|Bid||83.73 x 200|
|Ask||83.85 x 500|
|Day's Range||83.10 - 84.04|
|52 Week Range||75.81 - 100.51|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 25, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||114.30|
Tetraphase Pharmaceuticals (TTPH) is a clinical-stage biopharmaceutical company focused on creating novel antibiotics. These antibiotics treat serious and life-threatening multidrug-resistant infections by using the company’s proprietary chemistry technology. Its lead product candidate is eravacycline, which is being developed as an intravenous antibiotic.
SAN RAFAEL, Calif. , April 18, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
Spark Therapeutics (ONCE) is a leader in the field of gene therapy. Spark Therapeutics’ pipeline of gene therapy product candidates targets the retina, liver, and the central nervous system. Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations, and ten have given it “buy” recommendations.
Achaogen (AKAO), a late-stage biopharmaceutical company, develops and commercializes antibacterial treatments for MDR (multidrug-resistant) gram-negative infections. Its lead product candidate, plazomicin, targets serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, which was identified as a “nightmare bacteria” by the Centers for Disease Control and Prevention in 2013. Of the 12 analysts covering Achaogen in April 2018, five have recommended a “strong buy,” six have recommended a “buy,” and one has recommended a “sell.” The mean rating for the stock is 1.8, and its target price is $21.56.
CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with liver disease and other chronic diseases. Of the eight analysts covering CymaBay Therapeutics in April 2018, two analysts have given the stock a “strong buy” rating, and six analysts have given it a “buy” rating. Of the total 22 analysts covering Pfizer (PFE) in April 2018, two analysts have given the stock a “strong buy” rating, and nine analysts have given it a “buy” rating.
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
With the announcement of Novartis (NVS) acquiring AveXis, a clinical stage gene therapy company, several companies have started to develop the therapy with many of them having promising candidates in their pipelines.
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
NEW YORK, NY / ACCESSWIRE / April 13, 2018 / U.S. markets jumped Thursday as investor’s attention shifted from current geopolitical tensions to the upcoming earnings season. Bank stocks were the top gainers ...
Increase in profitability and industry-beating performance can be essential considerations in a stock for some investors. In this article, I will take a look at BioMarin Pharmaceutical Inc’s (NASDAQ:BMRN) trackRead More...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
On April 9, 2018, Novartis AG (NVS) announced that it had entered into an agreement to acquire AveXis (AVXS), a clinical-stage gene therapy company, for ~$8.7 billion.
Take a look at Morningstar analysts' nine 'exponential technology' themes and some undervalued stocks poised to benefit from them.
Audentes, Spark and uniQure popped Tuesday after Novartis' $8.7 billion plan to buy AveXis put a spotlight on other gene therapy players.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding BMRN is favorable, with net inflows of $7.66 billion.
Roche offered additional details Thursday on the deaths of five patients taking its potential blockbuster drug Hemlibra.
BioMarin's (BMRN) MAA submission for its pipeline PKU candidate, pegvaliase, gets accepted in the EU. The same is under priority review in the United States with decision awaited this May.
SAN RAFAEL, Calif., March 28, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) announced today that the European Medicines Agency (EMA) has accepted BioMarin's submission of a Marketing Authorization Application (MAA) for pegvaliase, a PEGylated recombinant phenylalanine ammonia lyase enzyme product, for the treatment of adults with phenylketonuria (PKU) who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 micromol/l) despite prior management with available treatment options including sapropterin. The U.S. Food and Drug Administration accepted the Biologics License Application (BLA) for pegvaliase and granted priority review status in August 2017, with the Prescription Drug User Fee Act (PDUFA) Action Goal Date of May 25, 2018.